Evidence map›Paper›PMID 38520085›Full record

Observational studyHIV medicine2024

Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study.

Shobna Sawry, Kassahun Ayalew, Gloria Maimela, Melissa Briggs-Hagen, Marelize van Wyk-Heath, Simangele Mthethwa, Sannie Shai, Nkululeko N Mngomezulu, Lawrence Tlhowe, Josephine Achere-Darko and 4 more

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in HIV medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 3 countries.

Shobna SawryWits RHI, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0002-3845-4863
Kassahun AyalewDivision of Global HIV and TB, Centers for Disease Control and Prevention (CDC), Pretoria, South Africa.
Gloria MaimelaWits RHI, University of the Witwatersrand, Johannesburg, South Africa.
Melissa Briggs-HagenDivision of Global HIV and TB, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
Marelize van Wyk-HeathDivision of Global HIV and TB, Centers for Disease Control and Prevention (CDC), Pretoria, South Africa.
Simangele MthethwaDivision of Global HIV and TB, Centers for Disease Control and Prevention (CDC), Pretoria, South Africa.
Sannie ShaiWits RHI, University of the Witwatersrand, Johannesburg, South Africa.
Nkululeko N MngomezuluWits RHI, University of the Witwatersrand, Johannesburg, South Africa.
Lawrence TlhoweWits RHI, University of the Witwatersrand, Johannesburg, South Africa.
Josephine Achere-DarkoWits RHI, University of the Witwatersrand, Johannesburg, South Africa.
Jason BedfordDivision of Global HIV and TB, Centers for Disease Control and Prevention (CDC), Pretoria, South Africa.
Catherine E MartinWits RHI, University of the Witwatersrand, Johannesburg, South Africa.
Lee FairlieWits RHI, University of the Witwatersrand, Johannesburg, South Africa.
John ImrieWits RHI, University of the Witwatersrand, Johannesburg, South Africa.
University of the Witwatersrand · ZACenters for Disease Control and Prevention · UGCenters for Disease Control and Prevention · US

Funding

CDC HHS
6 · The paper itself

Abstract

introductionAlthough dolutegravir (DTG) is deemed stable, safe, cost-effective, and clinically beneficial, it also carries the risk of side effects, including observed weight gain among patients on DTG-based antiretroviral therapy (ART) regimens. We compared weight changes among adults (≥18 years) initiating tenofovir disoproxil fumarate, lamivudine, and dolutegravir (TLD) or tenofovir disoproxil fumarate, emtricitabine, and efavirenz (TEE) regimens and those switching from TEE to TLD (TEE-to-TLD switchers) in three large primary care facilities in South Africa

methodsWe conducted a retrospective longitudinal record review using patient medical records, extracting relevant demographic and clinical data from October 2018 to June 2021 from randomly selected adults who initiated TLD or TEE (initiators) and adult TEE-to-TLD switchers. We assessed weight, body mass index (BMI), and percentage weight changes for both groups and fitted linear regression and generalized linear models to determine factors associated with weight and BMI change and percentage weight change ≥10%, respectively, among treatment initiators. We fitted linear mixed-effect models among TEE-to-TLD switchers to consider repeated measures.

resultsOf 860 initiators, 450 (52.3%) initiated on TEE and 410 (47.7%) on TLD, with median follow-up of 1.4 years and 1.0 year, respectively. At initiation, 43.3% on TEE and 40.8% on TLD were overweight or obese. TLD initiators had an adjusted higher mean weight gain of 1.6 kg (p < 0.001) and mean BMI gain of 0.51 kg/m

conclusionsWe report more weight gain among TLD than among TEE initiators, although to a lesser extent than previously reported. TEE-to-TLD switchers experienced less weight gain after TLD switch; return to health before receiving TLD may be a contributory factor. The current findings are reassuring for those switching to a DTG-based regimen.

Indexed as

AlkynesBenzoxazinesCyclopropanesHeterocyclic Compounds, 3-RingHIV InfectionsOxazinesPyridonesWeight GainAdultAnti-HIV AgentsBody Mass IndexDolutegravirEmtricitabineFemaleHumansLamivudineAlkynesAnti-HIV AgentsBenzoxazinesCyclopropanesDolutegravirefavirenzEmtricitabineHeterocyclic Compounds, 3-RingLamivudineOxazinesPiperazinesPyridonesTenofovirARTdolutegravirHIVroutine careweight gain

Identifiers

PMID38520085
PMCPMC11263972
OpenAlexW4393118349

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.